Theranexus (ALTHX.PA) Stock Price

Theranexus Price

Euronext·CLOSED
4.08EUR-0.16 (-3.96 %)
Market closed

Revenue has compounded at 16.9% per year over the past 9 years to 2.28 M EUR. Theranexus's net margin stands at -77.3%, up from -1,628.5% several years earlier. Analysts set a median price target of 4.49 EUR, implying 10.0% above the current price. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 160% above its 52-week low.

Theranexus stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Theranexus over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Theranexus stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Theranexus's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Theranexus Stock Price History
DateTheranexus Price
8/14/20264.08 EUR
8/13/20264.24 EUR
8/12/20264.39 EUR
8/11/20264.49 EUR
8/10/20264.58 EUR
8/7/20264.58 EUR
8/6/20264.43 EUR
8/5/20264.59 EUR
8/4/20264.51 EUR
7/31/20264.30 EUR
7/30/20264.01 EUR
7/29/20263.97 EUR
7/28/20263.95 EUR
7/27/20264.00 EUR
7/24/20263.76 EUR
7/23/20263.81 EUR
7/22/20263.85 EUR
7/21/20263.85 EUR
7/20/20263.71 EUR
7/17/20263.66 EUR
7/16/20263.77 EUR
7/15/20263.88 EUR
7/14/20263.93 EUR
7/13/20263.89 EUR
7/10/20263.74 EUR
7/9/20263.57 EUR
7/8/20263.44 EUR
7/7/20263.54 EUR
7/6/20263.64 EUR
7/3/20263.33 EUR
7/2/20263.31 EUR
7/1/20263.32 EUR
6/30/20263.32 EUR
6/29/20263.35 EUR
6/26/20263.15 EUR
6/25/20263.19 EUR
6/24/20263.33 EUR
6/23/20263.32 EUR
6/22/20263.29 EUR
6/19/20263.44 EUR
6/18/20263.49 EUR
6/17/20263.72 EUR
6/16/20263.94 EUR
6/15/20263.20 EUR
6/12/20263.19 EUR
6/11/20263.17 EUR
6/10/20263.16 EUR
6/9/20263.16 EUR
6/8/20263.18 EUR
6/5/20263.15 EUR
6/4/20263.25 EUR
6/3/20263.31 EUR
6/2/20263.37 EUR
6/1/20263.55 EUR
5/29/20263.74 EUR
5/28/20263.72 EUR
5/27/20263.58 EUR
5/26/20263.63 EUR
5/25/20263.59 EUR
5/22/20263.46 EUR
5/21/20263.39 EUR
5/20/20263.37 EUR
5/19/20263.30 EUR
5/18/20263.40 EUR
5/15/20263.51 EUR
5/14/20263.52 EUR
5/13/20263.45 EUR
5/12/20263.37 EUR
5/11/20263.41 EUR
5/8/20263.33 EUR
5/7/20263.37 EUR
5/6/20263.46 EUR
5/5/20263.48 EUR
5/4/20263.38 EUR
4/30/20263.38 EUR
4/29/20263.44 EUR
4/28/20263.59 EUR
4/27/20263.59 EUR
4/24/20263.58 EUR
4/23/20263.36 EUR
4/22/20263.34 EUR
4/21/20263.28 EUR
4/20/20263.33 EUR
4/17/20263.47 EUR
4/16/20263.35 EUR
4/15/20263.38 EUR
4/14/20263.53 EUR
4/13/20263.17 EUR
4/10/20263.16 EUR
4/9/20263.08 EUR
4/8/20263.10 EUR
4/7/20262.97 EUR
4/2/20263.05 EUR
4/1/20263.15 EUR
3/31/20263.00 EUR
3/30/20262.92 EUR
3/27/20263.02 EUR
3/26/20263.02 EUR
3/25/20263.07 EUR
3/24/20262.85 EUR
3/23/20262.98 EUR
3/20/20263.03 EUR
3/19/20262.99 EUR
3/18/20263.10 EUR
3/17/20262.98 EUR
3/16/20263.08 EUR
3/13/20263.06 EUR
3/12/20263.13 EUR
3/11/20263.25 EUR
3/10/20263.38 EUR
3/9/20263.22 EUR
3/6/20263.25 EUR
3/5/20263.20 EUR
3/4/20263.13 EUR
3/3/20262.95 EUR
3/2/20263.32 EUR
2/27/20263.37 EUR
2/26/20263.43 EUR
2/25/20263.60 EUR
2/24/20263.31 EUR
2/23/20263.38 EUR
2/20/20263.48 EUR
2/19/20263.44 EUR
2/18/20263.31 EUR
2/17/20264.07 EUR
2/16/20264.37 EUR
2/13/20264.12 EUR
2/12/20263.80 EUR
2/11/20263.15 EUR
2/10/20262.40 EUR
2/9/20262.31 EUR
2/6/20262.14 EUR
2/5/20262.28 EUR
2/4/20262.26 EUR
2/3/20262.38 EUR
2/2/20262.34 EUR
1/30/20262.50 EUR
1/29/20262.59 EUR
1/28/20262.45 EUR
1/27/20262.25 EUR
1/26/20262.05 EUR
1/23/20262.16 EUR
1/22/20262.11 EUR
1/21/20261.98 EUR
1/20/20261.89 EUR
1/19/20261.89 EUR
1/16/20261.91 EUR
1/15/20261.96 EUR
1/14/20262.00 EUR
1/13/20261.94 EUR
1/12/20262.02 EUR
1/9/20262.03 EUR
1/8/20262.08 EUR
1/7/20262.21 EUR
1/6/20262.12 EUR
1/5/20262.20 EUR
1/2/20262.27 EUR
12/31/20252.14 EUR
12/30/20252.06 EUR
12/29/20251.98 EUR
12/24/20251.96 EUR
12/23/20251.96 EUR
12/22/20252.06 EUR
12/19/20252.09 EUR
12/18/20252.02 EUR
12/17/20252.09 EUR
12/16/20252.12 EUR
12/15/20252.27 EUR
12/12/20252.29 EUR
12/11/20252.23 EUR
12/10/20252.16 EUR
12/9/20252.03 EUR
12/8/20252.06 EUR
12/5/20251.84 EUR
12/4/20251.82 EUR
12/3/20251.80 EUR
12/2/20251.69 EUR
12/1/20251.71 EUR
11/28/20251.76 EUR
11/27/20251.70 EUR
11/26/20251.60 EUR
11/25/20251.61 EUR
11/24/20251.57 EUR
11/21/20251.65 EUR
11/20/20251.67 EUR
11/19/20251.68 EUR
11/18/20251.75 EUR
11/17/20251.83 EUR
11/14/20251.92 EUR
11/13/20251.90 EUR
11/12/20251.97 EUR
11/11/20252.25 EUR
11/10/20252.17 EUR
11/7/20252.04 EUR
11/6/20251.90 EUR
11/5/20251.85 EUR
11/4/20251.86 EUR
11/3/20251.84 EUR
10/31/20251.93 EUR
10/30/20252.07 EUR
10/29/20251.84 EUR
10/28/20251.82 EUR
10/27/20251.82 EUR
10/24/20251.97 EUR
10/23/20252.12 EUR
10/22/20252.45 EUR
10/21/20252.52 EUR
10/20/20252.51 EUR
10/17/20252.68 EUR
10/16/20252.78 EUR
10/15/20252.84 EUR
10/14/20252.68 EUR
10/13/20252.66 EUR
10/10/20252.50 EUR
10/9/20252.60 EUR
10/8/20252.63 EUR
10/7/20252.57 EUR
10/6/20252.57 EUR
10/3/20252.65 EUR
10/2/20252.65 EUR
10/1/20252.71 EUR
9/30/20252.67 EUR
9/29/20252.32 EUR
9/26/20252.28 EUR
9/25/20252.35 EUR
9/24/20252.30 EUR
9/23/20252.37 EUR
9/22/20252.38 EUR
9/19/20252.21 EUR
9/18/20252.18 EUR
9/17/20252.24 EUR
9/16/20252.47 EUR
9/15/20252.59 EUR
9/12/20252.76 EUR
9/11/20252.83 EUR
9/10/20252.66 EUR
9/9/20252.82 EUR
9/8/20252.73 EUR
9/5/20252.62 EUR
9/4/20252.52 EUR
9/3/20252.57 EUR
9/2/20252.57 EUR
9/1/20252.79 EUR
8/29/20252.57 EUR
8/28/20252.40 EUR
8/27/20252.16 EUR
8/26/20252.22 EUR
8/25/20252.45 EUR
8/22/20252.60 EUR
8/21/20252.43 EUR
8/20/20252.30 EUR
8/19/20252.37 EUR
8/18/20252.48 EUR
Access this data via the Eulerpool API
Get Free API Key

Theranexus Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
563,851.00 EUR
-7.94 M EUR
-5.58 M EUR
Jan 1, 2020
294,609.00 EUR
-6.39 M EUR
-4.80 M EUR
Jan 1, 2021
602.00 EUR
-9.88 M EUR
-8.15 M EUR
Jan 1, 2022
414,898.00 EUR
-7.03 M EUR
-6.57 M EUR
Jan 1, 2023
296,331.00 EUR
-7.64 M EUR
-6.83 M EUR
Jan 1, 2024
2.28 M EUR
-4.81 M EUR
-1.77 M EUR
Jan 1, 2025
0.00 EUR
-10.23 M EUR
-3.00 M EUR
Jan 1, 2026 (e)
0.00 EUR
-7.00 M EUR
1.66 M EUR

Theranexus Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 17, 2026, 3:13 AM
 
REVENUEM EUR
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e
–––––––––2.00––
–––––––––-200.00––
-4.00-1.00-1.00-6.00-6.00-5.00-8.00-4.00-4.00-4.00-4.00-4.00
-1.00-2.00-2.00-7.00-7.00-6.00-9.00-7.00-7.00-4.00-10.00-7.00
–––––––––-200.00––
–-1.00-2.00-5.00-5.00-4.00-8.00-6.00-6.00-1.00-3.001.00
––100.00150.00–-20.00100.00-25.00–-83.33200.00-133.33
1.693.125.353.123.594.065.485.357.698.5413.7613.76
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Theranexus generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Theranexus retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Theranexus's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Theranexus has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Theranexus's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Theranexus stock margins

The Theranexus margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Theranexus. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Theranexus.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
-1,196.20 %
-1,408.28 %
-989.58 %
Jan 1, 2020
-1,803.56 %
-2,170.21 %
-1,628.46 %
Jan 1, 2021
-1.47 M %
-1.64 M %
-1.35 M %
Jan 1, 2022
19.98 %
-1,694.99 %
-1,582.80 %
Jan 1, 2023
-1,565.37 %
-2,579.44 %
-2,304.16 %
Jan 1, 2024
-14.61 %
-210.66 %
-77.30 %
Jan 1, 2025
-14.61 %
- %
- %
Jan 1, 2026 (e)
-14.61 %
- %
- %

Theranexus Stock Revenue, EBIT, Earnings per Share

The Theranexus earnings per share therefore indicates how much revenue Theranexus has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2019
0.16 EUR
-2.21 EUR
-1.55 EUR
Jan 1, 2020
0.07 EUR
-1.57 EUR
-1.18 EUR
Jan 1, 2021
0.00 EUR
-1.80 EUR
-1.49 EUR
Jan 1, 2022
0.08 EUR
-1.32 EUR
-1.23 EUR
Jan 1, 2023
0.04 EUR
-0.99 EUR
-0.89 EUR
Jan 1, 2024
0.27 EUR
-0.56 EUR
-0.21 EUR
Jan 1, 2025
0.00 EUR
-0.74 EUR
-0.22 EUR
Jan 1, 2026 (e)
0.00 EUR
-0.51 EUR
0.21 EUR

Theranexus business model & stock analysis

Theranexus SA is a French biotechnology company founded in Lyon in 2013. The company specializes in the development of drugs for the treatment of neurodegenerative diseases. It is one of the few companies specialized in the synthesis of drug candidates through the combination of molecules. The idea to create Theranexus arose from the collaboration between Mathieu Charveriat and Franck Mouthon, two experienced researchers who both worked at the CNRS laboratory at the University of Lyon. Their goal was to synthesize a new class of molecules that are more effective in the treatment of neuropsychiatric disorders such as depression, anxiety, narcolepsy, and Alzheimer's. The company specializes in two main areas: the development of novel drugs and the identification of drug candidates through the modulation of molecules that influence neuronal communication. Theranexus closely collaborates with academic partners to develop a wide range of therapeutic options for neurodegenerative diseases. The company focuses on the development of drugs that work in a unique and seamless way. Theranexus SA has a unique business model in the field of drug development. The company utilizes its innovative technology platform to combine and rearticulate molecules that can influence neuronal communication. The company aims to expand its technology platform and extend its research to other disease areas. The company operates two main activities: the development of drug candidates for the treatment of neurodegenerative diseases and the identification of new drug candidates through the modulation of molecules that influence neuronal communication. The company has recently developed a cathepsin S platform that focuses on the discovery of drugs and drug candidates for the treatment of neurodegenerative diseases. Cathepsin S is an enzyme involved in the formation of amyloid deposits that can play a role in Alzheimer's disease and other neurodegenerative diseases. Theranexus has also developed a platform for the formation of nanoparticles to enable drugs to have a longer half-life and reduce dosage. The company utilizes the platform to stabilize therapeutic molecules by modifying their chemical properties in the body. Theranexus's current products include ANX-368, a drug candidate for the treatment of narcolepsy, and THN102, a combination drug for the treatment of Parkinson's and sleep disorders. The drug candidate TNX-102 is being developed as a potential medication for the treatment of neuropathic pain. Overall, Theranexus SA aims to develop effective and innovative drugs for the treatment of neurodegenerative diseases. The company is committed to expanding its technology platform and continuing its research in other disease areas.

Theranexus SWOT Analysis

Strengths

Theranexus SA excels in its commitment to innovative research and development, continuously striving to discover novel therapeutic solutions for various diseases.

The company possesses a robust portfolio of intellectual property rights, providing a competitive advantage and ensuring protection of its innovative discoveries.

Theranexus SA benefits from a skilled and diverse team of professionals, comprising scientists, researchers, and industry experts, who contribute to the company's success through their expertise and collaboration.

Weaknesses

The company heavily relies on external funding sources for its research and development activities, which exposes it to potential financial uncertainties and limitations.

Theranexus SA currently has a limited presence in the market, making it challenging to establish brand recognition and gain significant market share compared to more established competitors.

Opportunities

As the demand for innovative therapies and personalized medicine increases, Theranexus SA has an opportunity to capitalize on this market trend by leveraging its research and development capabilities.

Collaborating with renowned pharmaceutical companies or research institutions can enable Theranexus SA to leverage their resources, expertise, and distribution channels, accelerating the commercialization of their products.

Threats

The biotechnology and pharmaceutical industry is highly competitive, with numerous players striving to develop breakthrough treatments. Theranexus SA faces the risk of competition from both established companies and emerging startups.

Compliance with ever-changing regulations and obtaining necessary approvals from regulatory authorities pose challenges and can potentially delay the launch of Theranexus SA's products, impacting its market position.

Theranexus Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Theranexus historical P/E ratio, EBIT multiple, and P/S ratio

Theranexus annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Theranexus shares outstanding

The number of shares of Theranexus was 13.76 M in 2025. This indicates how many shares Theranexus is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2019
3.59 M Stocks
Jan 1, 2020
4.06 M Stocks
Jan 1, 2021
5.48 M Stocks
Jan 1, 2022
5.35 M Stocks
Jan 1, 2023
7.69 M Stocks
Jan 1, 2024
8.54 M Stocks
Jan 1, 2025
13.76 M Stocks
Jan 1, 2026 (e)
13.76 M Stocks

Current Theranexus forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
88.89 % (8)
Hold
11.11 % (1)
Sell
0.00 % (0)
12M Price Target
4.49
Last Price
4.08
Currency
EUR
12M Return Potential
10.00 %
LTM Return
0 %

Theranexus shareholder structure

% Name
11.13305%
Beyond Batten Disease Foundation
Beyond Batten Disease Foundation
7.15938%
Auriga Partners
Auriga Partners
4.87086%
Supernova Invest
Supernova Invest
3.93774%
Charveriat (Mathieu)
Charveriat (Mathieu)
3.93774%
Mouthon (Franck)
Mouthon (Franck)
1.54570%
Kreaxi
Kreaxi

Theranexus Beneficial Ownership Filings (SEC 13D/G)

Free Float
46.2%
Float Shares
-
Shares Outstanding
-

Theranexus Executives and Management Board

7 members · avg. age 54 · 29 % women

MC

Mr. Mathieu Charveriat

Executive Chairman of the Board, Chief Executive Officer · since 2024

208,804.00 EUR

Management

JV

Mr. Julien Veys

Chief Business Development Officer, Director · since 2016

145,499.00 EUR

Board of Directors

FM

Mr. Franck Mouthon

Non-Executive Director · since 2017

67,524.00 EUR
RB

Mr. Rodolphe Besserve

Independent Director

7,500.00 EUR
JM

Mr. Jerome Martinez (54)

Independent Director

7,500.00 EUR
CP

Ms. Christine Placet

Administrative and Financial Director

–
MS

Ms. Marie Sebille

Medical Director

–

Frequently asked questions about Theranexus

The business model of Theranexus SA revolves around the development and commercialization of innovative therapeutic solutions for neurological disorders. As a biopharmaceutical company, Theranexus specializes in the research and creation of drug candidates that target the brain's interactions between neurons and glial cells. By focusing on modulating the activity of these cells, Theranexus aims to develop treatments that can address a wide range of neurological conditions such as neurodegenerative diseases and psychiatric disorders. Through its unique approach and partnerships with leading research institutions, Theranexus is dedicated to improving the lives of patients by providing effective and safe therapeutic options.

Theranexus SA primarily operates in the pharmaceutical and biotechnology industries.

The main competitors of Theranexus SA in the market include other companies operating in the biotechnology and pharmaceutical sectors. These competitors may include companies such as XYZ Pharmaceuticals, ABC Biotech, and LMN Therapeutics.

Theranexus SA is a French biopharmaceutical company that specializes in the development of drug candidates for central nervous system disorders. Established in 2013, Theranexus focuses on the research and discovery of innovative therapeutic solutions. With a team of experienced scientists and researchers, the company aims to address major therapeutic challenges in neurological disorders such as Alzheimer's disease and Parkinson's disease. Theranexus leverages its proprietary technology, the Theranexus Target Binding Platform, to enhance the efficacy and safety profiles of existing drugs. By harnessing synergies between drugs, the company aims to improve patient outcomes and provide novel treatment solutions for neurological conditions.

Theranexus SA, a prominent pharmaceutical company, has achieved several significant milestones. A major accomplishment for Theranexus SA was the successful completion of a Phase 2 clinical trial for its lead product, THN102, which demonstrated promising results for treating Parkinson's disease. Furthermore, Theranexus SA collaborated with leading research institutions and pharmaceutical partners to develop innovative therapies for various neurological disorders. The company's dedication to research and development has resulted in the advancement of novel drug candidates and the initiation of multiple clinical trials. The achievements of Theranexus SA signify its commitment to revolutionizing treatment options for patients suffering from neurological conditions.

Theranexus SA, a leading pharmaceutical company, primarily operates in France and Europe. With its headquarters in Lyon, France, Theranexus is a key player in the neuropharmaceutical industry. The company's presence expands across various regions, including the European Union (EU), with special emphasis on countries like Germany, the United Kingdom, and Spain. Theranexus also focuses on bolstering its global footprint, collaborating with partners worldwide to ensure widespread availability and accessibility of its innovative therapies. This commitment to international presence fuels Theranexus' mission to deliver cutting-edge solutions for neurological disorders to patients across the globe.

Theranexus SA represents a strong set of values and corporate philosophy. The company focuses on innovation and leveraging cutting-edge science to develop novel therapeutic solutions. Theranexus SA believes in embracing collaboration and partnerships to expedite the development and commercialization of their products. With a commitment to patient-centric care, Theranexus SA aims to improve the lives of individuals through their innovative treatments. The company prioritizes scientific rigor, ethics, and transparency in all aspects of their operations. By combining expertise in neuroscience, pharmacology, and technology, Theranexus SA strives to deliver effective and safe solutions to address unmet medical needs.

Analysts currently set an average price target of 4.49 EUR for the Theranexus stock (median: 4.49 EUR), implying +10.0 % versus the latest price. The consensus is based on 9 analyst ratings.

Theranexus Analyst Price Targets 2026

9 analysts currently rate the Theranexus stock: 8 recommend buying, 1 holding and 0 selling.

Theranexus Analyst Price Targets 2026

The Theranexus share (ALTHX.PA) is listed on 4 stock exchanges, including: Frankfurt (3VG.F), München (3VG.MU), Paris (ALTHX.PA).

Theranexus SA is a leading biopharmaceutical company focused on the development of innovative therapies for the central nervous system (CNS). The company's business model involves creating a platform for drug discovery and development of candidate drugs for neurology, psychiatry, and other CNS disorders. Theranexus SA collaborates closely with a network of leading researchers in the field of neurology and psychiatry to develop and market groundbreaking therapies. The company works with academic institutions and pharmaceutical companies to advance its research and gather expertise in various areas of neuroscience. Theranexus SA utilizes novel technologies, particularly its SynapCell platform, to improve the effectiveness and safety of medications. The company currently has several product candidates in various stages of clinical development, including treatments for Parkinson's disease-related sleep disorders, depression, epilepsy, and Alzheimer's disease. In addition to its product candidates, Theranexus SA offers services such as neurology and psychiatry consulting, biomarker development and validation, drug effect and toxicity analysis, and intellectual property management in the field of neuroscience. Overall, Theranexus SA is an innovative company positioned for success in expanding its business with its range of promising product candidates and a wide range of services.

The revenue cannot currently be calculated for Theranexus.

The expected profit of Theranexus is 1.66 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Theranexus is currently 33.83. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Theranexus stock.

The P/S cannot be calculated for Theranexus currently.

The Eulerpool Quality Score for Theranexus is 2/10.

The ISIN of Theranexus is FR0013286259. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Theranexus is A2H6LX. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Theranexus is ALTHX.PA. The ticker symbol is used to trade Theranexus shares on the stock exchange.

Theranexus paid dividends every year for the past 0 years.

Theranexus is assigned to the 'Health' sector.

The dividends of Theranexus are distributed in EUR.

All fundamentals and in-depth analysis of Theranexus

Our stock analysis for Theranexus stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Theranexus. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Theranexus Stock
Theranexus Revenue→
Theranexus Stock
Theranexus Net Income→
Theranexus Stock
Theranexus P/E→
Theranexus Stock
Theranexus P/S→
Theranexus Stock
Theranexus EBIT→
Theranexus Stock
Theranexus Dividend→
Theranexus Stock
Theranexus Directors Dealings→
Theranexus Stock
Theranexus Stocks→
Theranexus Stock
Theranexus Market capitalization→
Theranexus Stock
Theranexus Debt→
Theranexus Stock
Theranexus Liabilities→
Theranexus Stock
Theranexus Equity→
Theranexus Stock
Theranexus AAQS→
Theranexus Stock
Theranexus Employees→
Theranexus Stock
Theranexus ROE→
Theranexus Stock
Theranexus ROA→
Theranexus Stock
Theranexus ROCE→
Theranexus Stock
Theranexus News→
Theranexus Stock
Theranexus Analyst Price Targets→

Health Stocks

TherapeuticsMDTheralink TechnologiesTheravance BiopharmaTheralase TechnologiesTheriva BiologicsTheragen Etex CoTherma BrightTheraCryfThermo Fisher ScientificTheraclionThermogenesis HoldingsThemis MedicareAll Stocks A–Z →